Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway

Mostrar otras versiones (1)

Non-small cell lung cancer (NSCLC) accounts for >80% of all lung cancer cases, which are the leading cause of cancer-related mortality worldwide. The clinical efficacy of available therapies for NSCLC is often limited due to the development of resistance to anticancer drugs, particularly to cispl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Dan, Wu, Yan, Shao, Cuijie, Gao, Yong, Wang, Deqiang, Guo, Jiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072289/
https://www.ncbi.nlm.nih.gov/pubmed/29901163
http://dx.doi.org/10.3892/or.2018.6486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072289/
https://www.ncbi.nlm.nih.gov/pubmed/29901163
http://dx.doi.org/10.3892/or.2018.6486

Ejemplares similares